The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Interferon beta 1a for subcutaneous use (L03AB07)

Interferon beta 1a for intramuscular use (L03AB07)

Ponesimod (L04AA50)

Sapropterin (A16AX07)

Ciclosporin (L04AD01)

Tamoxifen (L02BA01)

Tocilizumab (L04AC07)

Sofosbuvir & Velpatasvir (J05AX69)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest start date of the contract is 01.11.2023. Based on this, the contract period is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest start date of the contract is 01.11.2023. Based on this, the contract period is a maximum of 24 months.